Home
Science
Therapeutic Strategy
Team
News
Contact
Contact
In the news
09.05.2024
Visgenx Announces Presentation of Data Supporting Potential of its Synthetic AAV DNA...
»
09.05.2024
ASGCT 2024 Poster Abstract
»
07.05.2024
ELOVL2 Enzyme Product Improves Retinal Function and Rejuvenates Retina Architecture in an...
»
04.05.2024
Visgenx to Present at the Second Annual 2024 Cell & Gene Therapy...
»
08.04.2024
Visgenx selected as a ‘2024 Cool Company’
»
07.12.2023
Visgenx and Charles River Announce Expansion of Gene Therapy Manufacturing Alliance
»
15.11.2023
Visgenx to Present at the 4th Annual Dry AMD Therapeutic Development Summit
»
25.10.2023
Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2...
»
11.09.2023
Visgenx Poster: Advancing Next Generation Therapies, West Coast Symposium
»
11.09.2023
Visgenx Presents Poster at the Cell and Gene Therapy: Advancing Next Generation...
»
29.06.2023
Visgenx Announces Positive Results from a Key Translational Study for its Gene...
»
05.06.2023
Visgenx Appoints William Pedranti as Chief Executive Officer
»
24.05.2023
Attending BIO 2023? Click below to send Visgenx a meeting request in the...
»
15.05.2023
Visgenx to present at the American Society of Gene and Cell Therapy...
»
Load More
Reversal in Focus.
We aim to “turn back the clock” to a more youthful level of ELOVL2 expression.
Contact us
»
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Accept
Privacy Policy